Yüklüyor......
Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis
Bevacizumab has demonstrated a survival benefit in patients with metastatic colorectal cancer (mCRC) when combined with chemotherapy. Several randomized clinical trials comparing the efficacy and toxicity of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) agains...
Kaydedildi:
| Yayımlandı: | Mol Clin Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4486826/ https://ncbi.nlm.nih.gov/pubmed/26171215 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2015.572 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|